Patents by Inventor W. Robert Taylor
W. Robert Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10054522Abstract: Systems, devices and methods are configured to prepare a specimen. A system may include a preparation device configured to mate with a specimen collection device. The preparation device may include an agitator member and a filter member. The filter member and the agitator member may be configured to move independently with respect to each other and the preparation platform member. The filter member may be configured to move linearly with respect to the preparation platform member and/or the agitator member, and the agitator member may be configured to move linearly and radially with respect to the preparation platform member and/or the agitator member. The system may also include a specimen collection device. The specimen may include but is not limited to fecal matter.Type: GrantFiled: May 16, 2016Date of Patent: August 21, 2018Inventors: Colleen Kraft, W. Robert Taylor, Michael L. Wach, Jonathan Shaw, Louis F. Malice
-
Patent number: 9795763Abstract: Delivery devices, systems, and methods are configured to enhance retention of a therapeutic agent delivered at a treatment site, for example, via impeding agent backflow. A device may include sheath having a first end, a second end, and a length between the first end and the second end. The sheath may include an outer diameter and an inner channel between the first end and the second end, and at least one penetrating member configured to form a channel at the treatment site. The device may include an elongate member having a first end, a second end, and a length between the first end and the second end, the elongate member being configured to move relative to the sheath. The elongate member may be configured to control the movement of the penetrating member with respect to the sheath.Type: GrantFiled: September 4, 2013Date of Patent: October 24, 2017Assignee: CELL PRECISION, LLCInventors: Michael L. Wach, Raymond P. Vito, Jack Griffis, W. Robert Taylor
-
Publication number: 20150238728Abstract: Delivery devices, systems, and methods are configured to enhance retention of a therapeutic agent delivered at a treatment site, for example, via impeding agent backflow. A device may include sheath having a first end, a second end, and a length between the first end and the second end. The sheath may include an outer diameter and an inner channel between the first end and the second end, and at least one penetrating member configured to form a channel at the treatment site. The device may include an elongate member having a first end, a second end, and a length between the first end and the second end, the elongate member being configured to move relative to the sheath. The elongate member may be configured to control the movement of the penetrating member with respect to the sheath.Type: ApplicationFiled: September 4, 2013Publication date: August 27, 2015Applicant: CELL PRECISION, LLCInventors: Michael L. Wach, Raymond P. Vito, Jack Griffis, W. Robert Taylor
-
Publication number: 20150050348Abstract: A medical practitioner can specify certain parameters for a procedure that involves delivering a therapeutic agent, while leaving other parameters open. The therapeutic agent can be sensitive to biomechanical forces (or other influences) associated with delivery. The procedure can involve regenerative medicine, for example delivering progenitor or stem cells to a diseased heart using a catheter, whereby unbridled transport in the catheter may compromise efficacy. The open parameters can influence efficacy of the agent and thus therapeutic outcome. A computer-based system can apply stored information, such as from databases, to narrow the possible values of the open parameters. From the narrowed possibilities, an optimization routine can determine suitable or optimized values for the open parameters. The determined values can manage biomechanical forces incurred by the therapeutic agent, thereby promoting efficacy and healing. The optimized parameters can guide the practitioner in the procedure.Type: ApplicationFiled: August 16, 2013Publication date: February 19, 2015Inventors: Raymond P. Vito, Jack C. Griffis, W. Robert Taylor, Michael L. Wach
-
Patent number: 8871268Abstract: Methods of manufacturing a three-dimensional, biodegradable, thermoset polymeric network composition having desirable degradation and mechanical properties, comprising a macromer component cross-linked with a monofunctional acrylate-containing component. The macromer component can comprise a diacrylate-containing component polymerized with an amine-containing component, wherein the molar ratio of the diacrylate-containing component to the amine-containing component is greater than or equal to 1.Type: GrantFiled: February 23, 2011Date of Patent: October 28, 2014Assignees: Georgia Tech Research Corporation, Emory UniversityInventors: David Safranski, Kenneth Gall, W. Robert Taylor, Daiana Weiss
-
Patent number: 8815860Abstract: The present disclosure is generally related to methods of preventing oxidative stress injury induced by renal ischemia-reperfusion by a Folate-TEMPOL conjugate.Type: GrantFiled: September 21, 2010Date of Patent: August 26, 2014Assignees: Emory University, Georgia Tech Research CorporationInventors: W. Robert Taylor, Sarah F. Knight, Niren Murthy, Kousik Kundu
-
Publication number: 20140105826Abstract: Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted ? conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended ? conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo.Type: ApplicationFiled: December 20, 2013Publication date: April 17, 2014Applicants: Emory University, Georgia Tech Research CorporationInventors: Niren Murthy, W. Robert Taylor, Kousik Kundu, Sarah F. Knight, Sungmun Lee
-
Patent number: 8628753Abstract: Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted ? conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended ? conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo.Type: GrantFiled: September 28, 2010Date of Patent: January 14, 2014Assignees: Emory University, Georgia Tech Research CorporationInventors: Niren Murthy, W. Robert Taylor, Kousik Kundu, Sarah F. Knight, Sungmun Lee
-
Publication number: 20140005595Abstract: Devices and methods for delivering therapeutic agents use a movable sheath member to deliver a therapeutic agent with little or no shear stress. The delivery device may include an outer body being configured to move away from a distal end of the delivery device. The movable sheath member may have a first section and a second section opposing the first section, the second section being configured to hold the therapeutic agent. The movable sheath may be configured to deliver the therapeutic agent by increasing the first section by moving the outer body away from the distal end.Type: ApplicationFiled: March 19, 2012Publication date: January 2, 2014Applicants: CELL PRECISION, LLC, EMORY UNIVERSITYInventors: W. Robert Taylor, Raymond P. Vito, Michael L. Wach, Jack Griffis
-
Publication number: 20130345634Abstract: Delivery devices, systems, and methods are configured to increase the retention of the therapeutic agent, and thereby increase the dose of the agent delivered. The delivery device may include a delivery body and a retractable member configured to move with respect to the delivery body. The retractable member may include a puncture member configured to create a delivery channel at the treatment site. The body may include an opening through which an agent may be delivered after the retractable member has been retracted within the device.Type: ApplicationFiled: June 24, 2013Publication date: December 26, 2013Inventors: Michael L. Wach, Raymond P. Vito, W. Robert Taylor, Jack Griffis
-
Publication number: 20130331777Abstract: Devices and methods for delivering therapeutic agents use an inverted member to deliver a therapeutic agent with little or no shear stress. The inverted member may have a movable continuous surface, the movable continuous surface having a first section and a second section opposing the first section, the second section surrounding an inner cavity that is configured to hold the therapeutic agent, the inverting member being configured to deliver the therapeutic agent by inverting at least a portion of the second section.Type: ApplicationFiled: March 19, 2012Publication date: December 12, 2013Applicants: CELL PRECISION, LLC, EMORY UNIVERSITYInventors: W. Robert Taylor, Raymond P. VIto, Michael L. Wach, Jack Griffis
-
Patent number: 8535291Abstract: A medical practitioner can specify certain parameters for a procedure that involves delivering a therapeutic agent, while leaving other parameters open. The therapeutic agent can be sensitive to biomechanical forces (or other influences) associated with delivery. The procedure can involve regenerative medicine, for example delivering progenitor or stem cells to a diseased heart using a catheter, whereby unbridled transport in the catheter may compromise efficacy. The open parameters can influence efficacy of the agent and thus therapeutic outcome. A computer-based system can apply stored information, such as from databases, to narrow the possible values of the open parameters. From the narrowed possibilities, an optimization routine can determine suitable or optimized values for the open parameters. The determined values can manage biomechanical forces incurred by the therapeutic agent, thereby promoting efficacy and healing. The optimized parameters can guide the practitioner in the procedure.Type: GrantFiled: May 7, 2012Date of Patent: September 17, 2013Assignee: Cell Precision, LLCInventors: Raymond P. Vito, Jack C. Griffis, III, W. Robert Taylor, Michael L. Wach
-
Publication number: 20120322895Abstract: Methods of manufacturing a three-dimensional, biodegradable, thermoset polymeric network composition having desirable degradation and mechanical properties, comprising a macromer component cross-linked with a monofunctional acrylate-containing component. The macromer component can comprise a diacrylate-containing component polymerized with an amine-containing component, wherein the molar ratio of the diacrylate-containing component to the amine-containing component is greater than or equal to 1.Type: ApplicationFiled: February 23, 2011Publication date: December 20, 2012Applicants: Emory University, Georgia Tech Research CorporationInventors: David Safranski, Kenneth Gall, W. Robert Taylor, Daiana Weiss
-
Publication number: 20120302575Abstract: The present disclosure is generally related to methods of preventing oxidative stress injury induced by renal is-chemia-reperfusion by a Folate-TEMPOL conjugate.Type: ApplicationFiled: September 21, 2010Publication date: November 29, 2012Applicants: GEORGIA TECH RESEARCH CORPORATION, EMORY UNIVERSITYInventors: W. Robert Taylor, Sarah F. Knight, Niren Murthy, Kousik Kundu
-
Patent number: 8197462Abstract: A medical practitioner can specify certain parameters for a procedure that involves delivering a therapeutic agent, while leaving other parameters open. The therapeutic agent can be sensitive to biomechanical forces (or other influences) associated with delivery. The procedure can involve regenerative medicine, for example delivering progenitor or stem cells to a diseased heart using a catheter, whereby unbridled transport in the catheter may compromise efficacy. The open parameters can influence efficacy of the agent and thus therapeutic outcome. A computer-based system can apply stored information, such as from databases, to narrow the possible values of the open parameters. From the narrowed possibilities, an optimization routine can determine suitable or optimized values for the open parameters. The determined values can manage biomechanical forces incurred by the therapeutic agent, thereby promoting efficacy and healing. The optimized parameters can guide the practitioner in the procedure.Type: GrantFiled: May 18, 2009Date of Patent: June 12, 2012Assignee: Cell Precision, LLCInventors: Raymond P. Vito, Michael L. Wach, Jack C. Griffis, III, W. Robert Taylor
-
Patent number: 8152755Abstract: A catheter for delivering a therapeutic agent to a target site of a human or animal subject can include a substantially flexible and biocompatible catheter body having a proximal end and a distal end. An eductor can be located at the distal end of the catheter body, and a first lumen within the catheter body for housing the therapeutic agent can be in fluid communication with the eductor. A second lumen, also in fluid communication with the first lumen, can extend from the proximal end of the catheter body towards the eductor and can have an output port at the distal end of the catheter body. The eductor can be operable to induce the therapeutic agent to flow from the first lumen out of the output port in response to fluid flowing through the second lumen.Type: GrantFiled: March 24, 2010Date of Patent: April 10, 2012Assignee: Cell Precision LLCInventors: Michael L. Wach, W. Robert Taylor, Jack C. Griffis, III, Raymond P. Vito
-
Patent number: 8147479Abstract: A physician, nurse, or other healthcare practitioner can deliver a therapeutic agent to a patient in a manner that maintains effectiveness of the therapeutic agent, via monitoring and controlling shear, stress, or other potentially detrimental effect. A gauge, meter, or other monitoring device can provide an indication of shear (or other effect) that the therapeutic agent is experiencing during delivery. The monitoring device can provide information relevant to delivering the therapeutic agent in a manner that maintains effectiveness, thereby guiding the practitioner during delivery. For example, the monitoring device can display an estimate of shear based on sensing flow rate or pressure. The therapeutic agent can comprise one or more therapeutic cells, such as progenitor cells or stem cells, or some other healing substance delivered via a cardiac catheter to the patient's cardiovascular tissue, for example.Type: GrantFiled: July 14, 2009Date of Patent: April 3, 2012Assignee: Cell Precision, LLCInventors: Michael L. Wach, W. Robert Taylor, Raymond P. Vito, Jack C. Griffis, III
-
Publication number: 20110070166Abstract: Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted ? conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended ? conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo.Type: ApplicationFiled: September 28, 2010Publication date: March 24, 2011Inventors: Niren Murthy, W. Robert Taylor, Kousik Kundu, Sarah F. Knight, Sungmun Lee